Dana-Farber Cancer Institute | Strategic Alliance Partners

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Andrew Hantel, MD, discusses the environmental and health impacts of decentralizing cancer care in response to high emissions generated by health care.

Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.